Aligning Science Across Parkinson's Logo Text

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease

Output Details

Published November 6, 2021

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for Parkinson’s disease (PD) and related synucleinopathies. They enable detection of seeding-competent alpha-synuclein aggregates in living patients and have shown high diagnostic accuracy in several PD and other synucleinopathy patient cohorts. However, there has been confusion about αSyn-SAAs for their methodology, nomenclature, and relative accuracies when performed by various laboratories. We compared αSyn-SAA results obtained from three independent laboratories to evaluate reproducibility across methodological variations. We utilized the Parkinson’s Progression Markers Initiative (PPMI) cohort, with DATSCAN data available for comparison, since clinical diagnosis of early de novo PD is critical for neuroprotective trials, which often use dopamine transporter imaging to enrich their cohorts. Blinded cerebrospinal fluid (CSF) samples for a randomly selected subset of PPMI subjects (30 PD, 30 HC, and 20 SWEDD), from both baseline and year 3 collections for the PD and HC groups (140 total CSF samples) were analyzed in parallel by each lab according to their own established and optimized αSyn-SAA protocols. The αSyn-SAA results were remarkably similar across laboratories, displaying high diagnostic performance (sensitivity ranging from 86 to 96% and specificity from 93 to 100%). The assays were also concordant for samples with results that differed from clinical diagnosis, including 2 PD patients determined to be clinically inconsistent with PD at later time points. All three assays also detected 2 SWEDD subjects as αSyn-SAA positive who later developed PD with abnormal DAT-SPECT. These multi-laboratory results confirm the reproducibility and value of αSyn-SAA as diagnostic tools, illustrate reproducibility of the assay in expert hands, and suggest that αSyn-SAA has potential to provide earlier diagnosis with comparable or superior accuracy to existing methods
Tags
  • Alpha-synuclein
  • Biomarker assay
  • Original Research

Meet the Authors

  • User avatar fallback logo

    Marco J Russo

    External Collaborator

  • User avatar fallback logo

    Christina D Orru

    External Collaborator

  • User avatar fallback logo

    Luis Concha-Marambio

    External Collaborator

  • User avatar fallback logo

    Simone Giaisi

    External Collaborator

  • User avatar fallback logo

    Bradley R Groveman

    External Collaborator

  • User avatar fallback logo

    Carly M. Farris

    External Collaborator

  • User avatar fallback logo

    Bret Holguin

    External Collaborator

  • User avatar fallback logo

    Andrew G. Hughson

    External Collaborator

  • User avatar fallback logo

    David-Erick Lafontant

    External Collaborator

  • User avatar fallback logo

    Chelsea Caspell-Garcia

    External Collaborator

  • User avatar fallback logo

    Christopher S. Coffey

    External Collaborator

  • User avatar fallback logo

    Jennifer Mollon

    External Collaborator

  • User avatar fallback logo

    Samantha J. Hutten

    External Collaborator

  • Kalpana Merchant, PhD

    Northwestern University

  • User avatar fallback logo

    Roland G. Heym

    External Collaborator

  • User avatar fallback logo

    Calaudio Soto

    External Collaborator

  • User avatar fallback logo

    Byron Caughey

    External Collaborator

  • User avatar fallback logo

    Un J Kang

    External Collaborator

Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.